TY - JOUR
T1 - SOX17
T2 - A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas
AU - Zhang, Xudong
AU - Yao, Jun
AU - Niu, Na
AU - Li, Xiaoran
AU - Liu, Yan
AU - Huo, Lei
AU - Euscher, Elizabeth D.
AU - Wang, Huamin
AU - Bell, Diana
AU - Sood, Anil K.
AU - Wang, Guoliang
AU - Lawson, Barrett C.
AU - Ramalingam, Preetha
AU - Malpica, Anais
AU - Sahin, Aysegul A.
AU - Ding, Qingqing
AU - Liu, Jinsong
N1 - Publisher Copyright:
© 2022 United States & Canadian Academy of Pathology
PY - 2023/2
Y1 - 2023/2
N2 - PAX8 is the most commonly used immunomarker to link a carcinoma to the gynecologic tract; however, it lacks specificity. Through mining The Cancer Genome Atlas mRNA expression profile data, we identified SOX17 as a potential specific marker at the mRNA level for gynecologic tumors. To evaluate the utility of this marker in the identification of the gynecologic origin of a given carcinoma, we performed immunochemical staining in a large cohort of ovarian and endometrial cancer cases (n = 416), together with a large cohort of solid tumors from other organs (n = 1544) in tissue microarrays. Similar to PAX8, SOX17 was highly expressed in different subtypes of ovarian carcinoma (97.5% for SOX17 vs 97% for PAX8 in serous carcinoma, 90% vs 90% in endometrioid carcinoma, and 100% vs 100% in clear cell carcinoma), except for mucinous carcinoma (0% vs 27%), and was also highly expressed in different subtypes of endometrial carcinoma (88% vs 84% in endometrioid carcinoma, 100% vs 100% in serous and clear cell carcinoma). SOX17 was not expressed in thyroid and renal cell carcinomas, whereas PAX8 expression was high (86% and 85%, respectively). In addition, SOX17 was expressed at low levels in cervical adenocarcinoma (20%) and had no expression in cervical squamous carcinoma, mesothelioma, and carcinomas from the breast, lung, pancreas, colon, stomach, liver, bladder, and salivary gland. Our data indicate that SOX17 is not only a sensitive but also a specific marker for the origin of ovarian and endometrial carcinomas.
AB - PAX8 is the most commonly used immunomarker to link a carcinoma to the gynecologic tract; however, it lacks specificity. Through mining The Cancer Genome Atlas mRNA expression profile data, we identified SOX17 as a potential specific marker at the mRNA level for gynecologic tumors. To evaluate the utility of this marker in the identification of the gynecologic origin of a given carcinoma, we performed immunochemical staining in a large cohort of ovarian and endometrial cancer cases (n = 416), together with a large cohort of solid tumors from other organs (n = 1544) in tissue microarrays. Similar to PAX8, SOX17 was highly expressed in different subtypes of ovarian carcinoma (97.5% for SOX17 vs 97% for PAX8 in serous carcinoma, 90% vs 90% in endometrioid carcinoma, and 100% vs 100% in clear cell carcinoma), except for mucinous carcinoma (0% vs 27%), and was also highly expressed in different subtypes of endometrial carcinoma (88% vs 84% in endometrioid carcinoma, 100% vs 100% in serous and clear cell carcinoma). SOX17 was not expressed in thyroid and renal cell carcinomas, whereas PAX8 expression was high (86% and 85%, respectively). In addition, SOX17 was expressed at low levels in cervical adenocarcinoma (20%) and had no expression in cervical squamous carcinoma, mesothelioma, and carcinomas from the breast, lung, pancreas, colon, stomach, liver, bladder, and salivary gland. Our data indicate that SOX17 is not only a sensitive but also a specific marker for the origin of ovarian and endometrial carcinomas.
KW - endometrial carcinoma
KW - marker
KW - ovarian carcinoma
KW - PAX8
KW - SOX17
UR - http://www.scopus.com/inward/record.url?scp=85149153947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149153947&partnerID=8YFLogxK
U2 - 10.1016/j.modpat.2022.100001
DO - 10.1016/j.modpat.2022.100001
M3 - Article
C2 - 36853778
AN - SCOPUS:85149153947
SN - 0893-3952
VL - 36
JO - Modern Pathology
JF - Modern Pathology
IS - 2
M1 - 100001
ER -